Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2025 07:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
April 02, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
March 25, 2025 08:00 ET | Source: Tiziana Life Sciences Ltd.

Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial

NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
December 13, 2023 07:30 ET | Source: Ocugen

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

MALVERN, Pa., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene...
October 11, 2021 08:00 ET | Source: CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals Inc. Featured in Syndicated Broadcast Covering Dosing of First Patients in Its Berubicin Clinical Development Program for Glioblastoma Multiforme

LOS ANGELES, Oct. 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- CNS Pharmaceuticals Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for...
July 24, 2019 07:25 ET | Source: Cure Pharmaceutical Holding Corp.

CURE Pharmaceutical [OTCQB:CURR] Secures Patent on High Loading of Active Ingredient in Oral Thin Films

OXNARD, Calif., July 24, 2019 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTC:CURR), an innovative drug delivery and development company, today announced the allowance of U.S. Application No....
May 29, 2019 09:00 ET | Source: Gofire, Inc.

Healthcare Tech Innovators Gofire Awarded U.S. Patent For Pioneering Precision-Dose ‘Smart Inhaler’

DENVER, May 29, 2019 (GLOBE NEWSWIRE) -- The United States Patent and Trademark Office (USPTO) has awarded healthcare technology leader Gofire™ its first patent for the company’s groundbreaking...
April 19, 2018 08:00 ET | Source: VBI Vaccines, Inc.

VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine

More than 1,600 subjects enrolled in PROTECT studyTopline data expected mid-2019 CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”) today announced...